The pCODR Expert Review Committee (pERC) has recommended the funding of Revlimid (lenalidomide) as a maintenance treatment for patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation conditional on the cost-effectiveness being improved to an acceptable level.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-revlimid-mm-fn-rec.pdf